VBIV VBI Vaccines Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of November 2016

 

000-13248

(Commission File Number)

 

VBI VACCINES INC.

(Exact name of Registrant as specified in its charter)

 

222 Third Street, Suite 2241

Cambridge, Massachusetts 02142

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.

 

Form 20-F [X] Form 40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____

 

 

 

On November 9, 2016, VBI Vaccines Inc., a corporation organized under the laws of British Columbia (the “ Company ”), filed on SEDAR at www.sedar.com its (i) unaudited Condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2016 (the “ Q3 Financial Statements ”), (ii) Management’s Discussion and Analysis for the three- and nine-month periods ended September 30, 2016 (the “ Q3 MD&A ”), (iii) Chief Executive Officer Certification of Interim Filings, dated November 9, 2016 (the “ CEO Certification ”) and (iv) Chief Financial Officer Certification of Interim Filings, dated November 9, 2016 (the “ CFO Certification ”). Copies of the Q3 Financial Statements, Q3 MD&A, CEO Certification and CFO Certification are attached hereto as Exhibits 99.1, 99.2, 99.3 and 99.4, respectively, and are incorporated herein by reference.

 

INCORPORATION BY REFERENCE

 

Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Number 333-212651) and Form S-8 (Registration Number 333-212160) of the Company and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

Exhibit Index

 

Exhibit No.		Description
99.1		Unaudited Condensed Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2016
99.2		Management’s Discussion and Analysis for the three- and nine-month periods ended September 30, 2016
99.3		Chief Executive Officer Certification of Interim Filings, dated November 9, 2016
99.4		Chief Financial Officer Certification of Interim Filings, dated November 9, 2016

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	VBI Vaccines Inc.
Date: November 9, 2016	By:	/s/ Jeff Baxter
		Jeff Baxter
		President and Chief Executive Officer